logo
Search orAI Icon𝛼SK
ENTITY
Biogen Inc

Biogen Inc (BIIB US)

142
Analysis
Health Care • United States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
bearish•Samsung Biologics
•13 Sep 2017 22:59

Biosimilar Battlefield: Samsung Bioepis Forecast

This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...

Logo
Share
bearish•Celltrion Healthcare
•08 Sep 2017 10:35

Surveying The Biosimilar Battlefield

The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS)  and...

Logo
Share
bullish•S&P 500 INDEX
•06 Sep 2017 23:22

U.S. Equity Strategy: Reiterating Biotechs, Gold Miners; Downgrading Financials to Market Weight

Key themes: Downgrading Financials. Given the Sector’s relative deterioration, we are downgrading Financials to market weight. Pockets of strength...

Logo
Vermilion Research
563 Views
Share
bullish•Samsung Biologics
•25 Jul 2017 21:50

Biogen Likes Biosimilars

Biogen Inc (BIIB US) , the partner of Samsung Biologics Co., Ltd (207940 KS) in the Samsung Bioepis JV, reported Q2 2017 results this morning and...

Logo
Share
bearish•Celltrion Inc
•19 Jul 2017 06:14

JNJ's REMICADE Holds: PFE's Results To Confirm

Johnson & Johnson (JNJ US) reported Q2 2017 results today (quotes from earnings call are below). US revenue for REMICADE (reference product for...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.7

x